Agile Therapeutics, Inc. (AGRX) At $3.39 Forms Top; Intuitive Surgical (ISRG)’s Sentiment Is 1.04

Intuitive Surgical, Inc. designs, manufactures, and markets da Vinci surgical systems, and related instruments and accessories. The company has market cap of $49.33 billion. The companyÂ’s da Vinci surgical System translates a surgeonÂ’s natural hand movements, which are performed on instrument controls at a console into corresponding micro-movements of instruments positioned inside the patient through small incisions or ports. It has a 77.64 P/E ratio. The Company’s da Vinci surgical system include surgeonÂ’s consoles, patient-side carts, 3-D vision systems, da Vinci skills simulators, da Vinci Xi integrated table motions, and Firefly fluorescence imaging products that enable surgeons to perform various surgical procedures, including gynecologic, urologic, general, cardiothoracic, and head and neck surgical procedures.

Agile Therapeutics, Inc. (AGRX) formed multiple top with $3.56 target or 5.00% above today’s $3.39 share price. Agile Therapeutics, Inc. (AGRX) has $115.89M valuation. The stock increased 2.11% or $0.07 during the last trading session, reaching $3.39. About 99,200 shares traded. Agile Therapeutics, Inc. (NASDAQ:AGRX) has declined 48.71% since January 27, 2017 and is downtrending. It has underperformed by 65.41% the S&P500.

Since January 1, 0001, it had 0 insider buys, and 13 selling transactions for $25.42 million activity.

Ratings analysis reveals 67% of Intuitive Surgical’s analysts are positive. Out of 3 Wall Street analysts rating Intuitive Surgical, 2 give it “Buy”, 0 “Sell” rating, while 1 recommend “Hold”. The lowest target is $760.0 while the high is $800.0. The stock’s average target of $780 is 77.18% above today’s ($440.24) share price. ISRG was included in 3 notes of analysts from October 13, 2016. The stock of Intuitive Surgical, Inc. (NASDAQ:ISRG) has “Outperform” rating given on Thursday, October 13 by Wells Fargo. The firm has “Buy” rating by Canaccord Genuity given on Wednesday, October 19. RBC Capital Markets maintained it with “Sector Perform” rating and $760.0 target in Wednesday, October 19 report.

The stock decreased 2.13% or $9.57 during the last trading session, reaching $440.24. About 1.82 million shares traded or 101.51% up from the average. Intuitive Surgical, Inc. (ISRG) has risen 39.52% since January 27, 2017 and is uptrending. It has outperformed by 22.82% the S&P500.

Biondo Investment Advisors Llc holds 8.46% of its portfolio in Intuitive Surgical, Inc. for 88,194 shares. Bender Robert & Associates owns 38,308 shares or 7.67% of their US portfolio. Moreover, Fcm Investments Tx has 6.7% invested in the company for 5,409 shares. The New York-based Cim Llc has invested 5.25% in the stock. Hudson Valley Investment Advisors Inc Adv, a New York-based fund reported 17,330 shares.

Among 6 analysts covering Agile Therapeutics (NASDAQ:AGRX), 4 have Buy rating, 0 Sell and 2 Hold. Therefore 67% are positive. Agile Therapeutics had 21 analyst reports since December 30, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Monday, November 6 by Cantor Fitzgerald. The firm earned “Buy” rating on Friday, July 28 by Noble Financial. The rating was downgraded by Janney Capital to “Hold” on Friday, December 22. The stock has “Hold” rating by William Blair on Friday, December 22. The firm has “Hold” rating given on Tuesday, December 26 by William Blair. The firm has “Buy” rating given on Monday, June 12 by Noble Financial. The company was maintained on Friday, December 22 by H.C. Wainwright. The stock has “Buy” rating by Noble Financial on Friday, December 22. The rating was initiated by Cantor Fitzgerald with “Buy” on Friday, January 8. The firm earned “Buy” rating on Friday, July 14 by RBC Capital Markets.

Analysts await Agile Therapeutics, Inc. (NASDAQ:AGRX) to report earnings on March, 14. They expect $-0.25 earnings per share, up 13.79% or $0.04 from last year’s $-0.29 per share. After $-0.22 actual earnings per share reported by Agile Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 13.64% negative EPS growth.